Pancreatic cancer drug Daraxonrasib doubles survival, but €35k/month price limits access

Daraxonrasib, approved in the US and nearing EU approval, doubles survival in pancreatic cancer but costs €35,000 monthly, making it unaffordable for most. The high price raises access and reimbursement concerns in Austria and elsewhere, potentially limiting real-world impact despite clinical efficacy.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works